BAL0891

P1, N=216, Recruiting, SillaJen, Inc. | N=120 --> 216

P1, N=120, Recruiting, SillaJen, Inc. | Trial primary completion date: Sep 2024 --> Jul 2025

BAL0891 combined with paclitaxel in vivo showed strong reproducible synergy in the TNBC BR1282 model, with a high percentage of complete cures. Synergistic anti-tumor effects were also observed with carboplatin in the ovarian SKOV-3 model. Strong BAL0891 single agent activity was previously reported; the current data support BAL0891 combination strategies in the clinic.

BAL0891 is a novel dual TTK/PLK1 mitotic checkpoint inhibitor with potent anti-cancer activity in TNBC models. Intermittent IV administration is well tolerated and associated with prolonged tumor drug exposure, prolonged TTK inhibition and notable anti-tumor efficacy. These data support further investigation of BAL0891 for the treatment of cancer patients (incl.

BAL0891 is a novel, dual TTK/PLK1 mitotic checkpoint inhibitor. In tumor cells, a prolonged effect on TTK combined with a transient effect on PLK1 contributes to rapid SAC disruption and aberrant mitotic exit, associated with potent single agent activity in mouse models of human cancer.